Last reviewed 2026-04-23 · How we verify

JMT103

JMT103 is a small molecule that targets the SGLT2 receptor.

JMT103 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Mechanism of action

By inhibiting the SGLT2 receptor, JMT103 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful for the treatment of type 2 diabetes.

Approved indications

• Type 2 diabetes

Common side effects

• Nausea
• Diarrhea
• Vomiting

Key clinical trials

• Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease (PHASE3)
• A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid (PHASE3)
• Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors (PHASE1)
• A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone (PHASE3)
• Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone (PHASE1, PHASE2)
• Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis (PHASE2)
• Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis (PHASE2)
• A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.